Last reviewed 2026-05-28 · How we verify

Theragran Hematinic

Ain Shams University · FDA-approved active Small molecule ✓ Verified May 2026

Theragran Hematinic is a Multivitamin and mineral supplement Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Iron deficiency anemia, Nutritional deficiency-related anemia, Hematinic supplementation.

Theragran Hematinic is a multivitamin and mineral supplement formulation designed to correct nutritional deficiencies and support hematopoiesis (blood cell formation).

Theragran Hematinic is a treatment for iron deficiency anemia in pregnancy, as studied in clinical trials. It is compared to low molecular weight iron dextran in the treatment of this condition.

At a glance

Generic name	Theragran Hematinic
Sponsor	Ain Shams University
Drug class	Multivitamin and mineral supplement
Modality	Small molecule
Therapeutic area	Hematology
Phase	FDA-approved

Mechanism of action

This hematinic formulation typically contains iron, B vitamins (including B12 and folate), and other cofactors essential for red blood cell production and prevention of anemia. By replenishing deficient micronutrients, it restores normal erythropoiesis and oxygen-carrying capacity of blood.

Approved indications

Iron deficiency anemia
Nutritional deficiency-related anemia
Hematinic supplementation

Common side effects

Gastrointestinal upset
Constipation
Nausea
Dark stools

Key clinical trials

Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Theragran Hematinic CI brief — competitive landscape report
Theragran Hematinic updates RSS · CI watch RSS
Ain Shams University portfolio CI

Frequently asked questions about Theragran Hematinic

What is Theragran Hematinic?

Theragran Hematinic is a Multivitamin and mineral supplement drug developed by Ain Shams University, indicated for Iron deficiency anemia, Nutritional deficiency-related anemia, Hematinic supplementation.

How does Theragran Hematinic work?

Theragran Hematinic is a multivitamin and mineral supplement formulation designed to correct nutritional deficiencies and support hematopoiesis (blood cell formation).

What is Theragran Hematinic used for?

Theragran Hematinic is indicated for Iron deficiency anemia, Nutritional deficiency-related anemia, Hematinic supplementation.

Who makes Theragran Hematinic?

Theragran Hematinic is developed and marketed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).

What drug class is Theragran Hematinic in?

Theragran Hematinic belongs to the Multivitamin and mineral supplement class. See all Multivitamin and mineral supplement drugs at /class/multivitamin-and-mineral-supplement.

What development phase is Theragran Hematinic in?

Theragran Hematinic is FDA-approved (marketed).

What are the side effects of Theragran Hematinic?

Common side effects of Theragran Hematinic include Gastrointestinal upset, Constipation, Nausea, Dark stools.

Drug class: All Multivitamin and mineral supplement drugs
Manufacturer: Ain Shams University — full pipeline
Therapeutic area: All drugs in Hematology
Indication: Drugs for Iron deficiency anemia
Indication: Drugs for Nutritional deficiency-related anemia
Indication: Drugs for Hematinic supplementation

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing